Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
- 1 January 2009
- journal article
- guideline
- Published by Elsevier in Genetics in Medicine
- Vol. 11 (1) , 15-20
- https://doi.org/10.1097/gim.0b013e31818efd9d
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based reviewGenetics in Medicine, 2009
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working GroupGenetics in Medicine, 2009
- UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with IrinotecanClinical Cancer Research, 2007
- Management of advanced colorectal cancer: state of the artBritish Journal of Cancer, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan‐based chemotherapyCancer, 2006
- Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to IrinotecanDrug Metabolism Reviews, 2006
- Rapid Detection of UGT1A1 Gene Polymorphisms by Newly Developed Invader AssayClinical Chemistry, 2004
- The treatment of advanced colorectal cancer: where are we now and where do we go?Best Practice & Research Clinical Gastroenterology, 2002
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002